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FAS belongs to the subgroup of the tumor necrosis factor receptor (TNF-R) family that contains an intracel-
lular ‘‘death domain’’ and triggers apoptosis. Its physiological ligand FASL is a member of the TNF cytokine
family. Studies with mutant mice and cells from human patients have shown that FAS plays critical roles in the
immune system, including the killing of pathogen-infected cells and the death of obsolete and potentially
dangerous lymphocytes. Fas thereby functions as a guardian against autoimmunity and tumor development.
FAS triggers apoptosis through FADD-mediated recruitment and activation of caspase-8. In certain cells
such as hepatocytes, albeit not lymphocytes, FAS-induced apoptosis requires amplification through proteo-
lytic activation of the proapoptotic BCL-2 family member BID. Curiously, several components of the FAS
signaling machinery have been implicated in nonapoptotic processes, including cellular activation, differen-
tiation, and proliferation. This review describes current understanding of Fas-induced apoptosis signaling
and proposes experimental strategies for future advances.Introduction
The cell surface-bound receptor FAS (also called APO-1 or
CD95) was originally discovered as the target of two monoclonal
antibodies that trigger apoptotic cell death in certain human
tumor-derived cell lines in culture or as xeno-transplants in
immunodeficient mice. Cloning of the gene encoding FAS re-
vealed that it is a member of the tumor necrosis factor receptor
(TNF-R) family (Itoh et al., 1991), which also includes the recep-
tors for TNF, TRAIL (TNF-related apoptosis-inducing ligand), and
those for othermembers of the TNF cytokine family. Accordingly,
identification of the physiological ligand for FAS, called FAS
ligand (FASL or CD95L) (Suda et al., 1993), through expression
cloning demonstrated that it belongs to the TNF cytokine family.
The discovery that certain spontaneous mutant mouse strains
that develop lymphadenopathy and SLE (systemic lupus erythe-
matosus)-like autoimmune disease carry homozygous defects in
the genes encoding FAS (Faslpr/lpr or Faslprcg/lprcg) (Watanabe-
Fukunaga et al., 1992) or FASL (Faslgld/gld) (Takahashi et al.,
1994) and the realization that a large fraction of human ALPS
(autoimmune lympho-proliferative syndrome) patients have
heterozygous inherited mutations in the FAS gene (Fisher
et al., 1995; Rieux-Laucat et al., 1995) demonstrated that
FASL-FAS signaling plays a critical role in the control of the
immune system. ALPS patients (Straus et al., 2001) as well as
the FAS- or FASL-deficient mice have an abnormally increased
predisposition to lymphoma development, demonstrating that
FASL-FAS signaling is also critical for tumor suppression, at
least within the lymphoid compartment. FASL expressed on acti-
vated T lymphocytes or natural killer (NK) cells contributes to
their ability to kill target cells, such as virus-infected or damaged
cells. Abnormally increased FASL-mediated killing of healthy
(FAS+) bystander cells has been implicated in certain immuno-
pathological states, such as hepatitis induced by extensive
T cell activation. Pharmacological modulation of the FASL-FAS
signaling machinery may therefore be a useful strategy for ther-180 Immunity 30, February 20, 2009 ª2009 Elsevier Inc.apeutic intervention in certain diseases, but caution is warranted
because administration of agonistic FAS-specific antibodies
(Ogasawara et al., 1993) or FASL (Huang et al., 1999) cause
extensive hepatocyte apoptosis and fatal hepatitis in mice.
Detailed understanding of FASL-FAS signaling may allow the
development ofmore subtle intervention strategies and, interest-
ingly, one FAS-specific antibody was shown to cure Faslgld/gld
mutant mice from their lymphadenopathy without causing liver
toxicity (Ichikawa et al., 2000).
Mechanisms of FASL-FAS Signaling Induced Apoptosis
It has been argued that researchers readily observe that FAS
stimulation causes apoptosis because activators of FAS
(agonistic antibodies or recombinantly produced forms of
FASL) have been selected for this property and that we may
therefore have overly emphasized this function of FASL-FAS
signaling while underestimating other activities, such as induc-
tion of cellular proliferation or differentiation (Peter et al., 2007).
However, activation of FAS by its physiological ligand, FASL,
has certainly been proven to trigger apoptosis (Krammer,
2000; Nagata, 1997). For example, several studies have shown
that cytotoxic T cells, which express FASL in membrane-bound
form (mFASL) on their surface, can kill FAS+ target cells, and
neutralization of FASL with specific antibodies or FAS-Fc fusion
proteins proved that this killing is mediated by FASL-induced
activation of FAS (Krammer, 2000; Nagata, 1997). Moreover,
restimulation of already activated normal T cells or T
lymphoma-derivedcell lines via their TCR (Tcell antigen receptor)
complex causes extensive suicide or fratricide, a process called
activation-induced cell death (AICD). (It has recently been
proposed to rename this process ‘‘restimulation-induced cell
death’’ [RICD] in order to distinguish it more clearly from the cell
death that can occur when naive T lymphocytes are stimulated
for the first time with antigen or mitogen.) Experiments with
Faslpr/lpr or Faslgld/gld mice or the aforementioned FASL blockers
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Figure 1. Death Receptor-Induced and
Bcl-2-Regulated Apoptosis Signaling
This figure shows the two distinct but ultimately
converging apoptosis signaling pathways in
mammals. One is activated by so-called death
receptors, members of the tumor necrosis factor
receptor (TNF-R) family with an intracellular death
domain, and requires FADD-mediated activation
of caspase-8 (shown on the right). Auto-process-
ing of caspase-8 results in a heterotetrameric
form of the protein that is able to activate the
zymogens of effector caspases, caspase-3 and
caspase-7, eventually leading to cleavage of vital
proteins within the cell, such as PARP or lamins,
or activation of the DNase CAD (caspase-acti-
vated DNase) by cleavage of its inhibitor, ICAD
(inhibitor of CAD). It is possible that caspase-8
may also proteolyze to a certain extent some of
the classical substrates of effector caspases. The
BCL-2-regulated pathway (shown on the left) is
arbitrated by the complex interplay between pro-
and antiapoptotic members of the BCL-2 protein
family and involves mitochondrial outer membrane
permeabilization (MOMP). MOMP results in
release of cytochrome C from the intermembrane
space of the mitochondria into the cytosol to
initiate apoptosome formation resulting in
APAF-1-mediated activation of the ‘‘initiator’’ cas-
pase, caspase-9, further leading to proteolytic
activation of the downstream effector caspases,
caspase-3 and caspase-7. Abbreviations: BH3-
only, BCL-2 homology domain 3 only protein;
MOMP, mitochondrial outer membrane permeabi-
lization; Cyt. C, cytochrome C; ICAD, Inhibitor of
caspase activated DNase (CAD); PARP, Poly
(ADP-ribose) polymerase.showed that this apoptosis is caused (at least in part) by physio-
logical FASL-FAS signaling (reviewed in Krammer [2000]; Nagata
[1997]). It is widely believed that defects in this process underlie
the lymphadenopathy and autoimmune disease that develop in
miceandhumans that haveabnormalities in their genes encoding
FAS or FASL (Krammer, 2000; Nagata, 1997).
Given that physiological FASL-FAS signaling can induce
apoptosis, we first describe the mechanisms of this process,
but nonapoptotic processes that are reportedly activated by
FAS will also be discussed. Elegant biochemical studies have
shown that ligation of FAS rapidly causes assembly of an intra-
cellular ‘‘death-inducing signaling complex’’ (DISC) (Kischkel
et al., 1995), which was shown to contain the aspartate-specific
cysteine protease, caspase-8 (Boldin et al., 1996; Muzio et al.,
1996), its adaptor/activator FADD (Boldin et al., 1995; Chin-
naiyan et al., 1995), and its modulator c-FLIP (FLICE [i.e., cas-
pase-8] inhibitory protein) (Irmler et al., 1997). The interaction
between FAS and FADD requires homotypic interaction of
‘‘death domains’’ (DD) (Boldin et al., 1995; Chinnaiyan et al.,
1995), which are present in the intracellular region of FAS also
in FADD (Figure 1). The recruitment of caspase-8 by FADD is
mediated (at least in part) by homotypic interaction of ‘‘death
effector domains’’ (DED) (Boldin et al., 1996; Muzio et al.,
1996), which are present in both proteins (Figure 1). Studies
with gene-targetedmice and transgenicmice expressing a domi-
nant-negative mutant of FADD (FADD-DN) or a viral enzymatic
inhibitor of caspase-8 (CRMA, cytokine response modifier A)demonstrated that FADD-mediated activation of the proteolytic
activity of caspase-8 is essential for FAS-induced apoptosis in
many (possibly all) cell types (including lymphoid and other
hemopoietic ones) both in vitro and within the whole animal
(Kang et al., 2004, 2008; Newton et al., 1998; Salmena et al.,
2003; Varfolomeev et al., 1998; Zhang et al., 1998). It is note-
worthy that in human cells, FAS activation also causes recruit-
ment of caspase-10 into the DISC and that in certain cell lines,
caspase-10 activation was reported to contribute to apoptosis
signaling. Mice do not have a gene encoding caspase-10, and
because the activation and function of caspase-10 are thought
to be very similar to those of caspase-8, wewill not deal with cas-
pase-10 in detail in this review. Caspase-8 activation within the
DISC occurs in two steps. First, recruitment of FADD to the
intracellular region of FAS promotes (via homotypic interaction
of ‘‘death effector domain’’ [DED] recruitment) dimerization and
a conformational change in caspase-8 within the DISC that
allows caspase-8 to gain full enzymatic activity (Boatright
et al., 2003). Second, active caspase-8 undergoes autoproteo-
lytic processing, which allows the enzyme to leave the DISC
and gain access to substrates in other cellular compartments
(Boatright et al., 2003). Experiments with caspase-8-deficient
(Casp8/) mice carrying a BAC transgene encoding WT cas-
pase-8 or a mutant of caspase-8 that has full enzymatic activity
but cannot cleave itself demonstrated that autoproteolysis of
caspase-8 is essential for FAS-induced apoptosis, at least in
lymphoid cells and hepatocytes (Kang et al., 2008). ThisImmunity 30, February 20, 2009 ª2009 Elsevier Inc. 181
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be able to trigger apoptosis, probably so that it can gain access
to critical proteolytic substrates. Active caspase-8 can proteolyt-
ically activate downstream effector caspases, such as caspase-
3 and caspase-7 (Figure 1), but (at least theoretically) this may
also directly contribute to cell demolition by proteolysis of certain
cellular proteins. During the later stages of apoptosis, effector
caspases perform the bulk of the proteolysis of vital cellular
proteins, such as structural components (e.g., lamins, gelsolin),
and they can also activate certain processes that dismantle non-
proteinaceaous cellular constituents (Salvesen and Dixit, 1997).
For example, effector caspase-mediated cleavage of ICAD
(inhibitor of caspase-activated DNase), which acts as both
a chaperone and inhibitor of CAD (caspase-activated DNase),
is critical for internucleosomal DNA cleavage, a hallmark of
apoptosis (Salvesen and Dixit, 1997).
The c-FLIP protein, which structurally resembles caspase-8
(presence of DED but no enzymatic activity), appears to affect
FAS-induced apoptosis in opposite ways depending on the
extent of its expression (Figure 1). At low concentration it is
thought to promote caspase-8 activation, possibly because cas-
pase-8 binds to c-FLIP with higher affinity than to itself (i.e., in
caspase-8 homodimerization). In contrast, at high concentration
c-FLIP reduces the proteolytic activity of caspase-8, possibly by
competing for binding to FADD, and thereby inhibits apoptosis
(Boatright et al., 2003). Studies with gene-targeted mice
confirmed that c-FLIP has a dual role, because its selective
loss in T lymphocytes or fibroblasts accelerated their Fas-
induced apoptosis (Zhang and He, 2005), although loss of
c-FLIP in all tissues pheno-copied the embryonic lethality seen
in Casp8/ mice (Yeh et al., 2000), which is caused by loss of
a nonapoptotic function of caspase-8 (Varfolomeev et al., 1998).
The proapoptotic BH3-only family member BID is a critical
substrate of caspase-8. Its proteolysis allows the truncated
BID (tBID) to translocate from the cytosol to the outer mitochon-
drial membrane, thereby unleashing its proapoptotic activity
(Figure 1; Li et al., 1998; Luo et al., 1998). BH3-only proteins
(BID, BAD, BIK [also called BLK or NBK], HRK [also called
DP5], BIM [also called BOD], NOXA, Puma [also called BBC3],
and BMF) form one of the two proapoptotic subgroups of the
BCL-2 protein family. Their name derives from the fact that
they share with each other and the BCL-2 family at large only
the 16–24 aa BH3 region (Huang and Strasser, 2000). The
BH3-only proteins are essential for initiation of developmentally
programmed cell death and stress-induced apoptosis and they
are activated in a death stimulus- as well as cell type-specific
manner (Huang and Strasser, 2000). BAX, BAK, and BOK belong
to the second proapoptotic (often called the ‘‘BAX-BAK’’ or
‘‘multi-BH domain’’) subgroup of the BCL-2 family. These
proteins contain three BH (BCL-2 homology) regions and
although they share surprisingly extensive structural similarity
to their prosurvival relatives, they are required for mitochondrial
outer membrane permeabilization (MOMP) and activation of the
caspase cascade in the ‘‘BCL-2-regulated’’ (also called ‘‘mito-
chondrial’’ or ‘‘intrinsic’’) apoptosis signaling pathway (Green
and Kroemer, 2004). The antiapoptotic BCL-2 family
members—BCL-2, BCL-XL, BCL-W, A1, and MCL-1—share
with each other up to four regions of homology (BH1, 2, 3, and
4) and are essential for cell survival, functioning in a cell type-182 Immunity 30, February 20, 2009 ª2009 Elsevier Inc.specific manner (Youle and Strasser, 2008). There are currently
two models to explain the functional interactions of the three
BCL-2 subgroups in apoptosis signaling. The ‘‘direct model’’
suggests that the BH3-only proteins bind and thereby activate
BAXand/orBAKdirectly and that theprosurvival relatives function
to bind and sequester theBH3-only proteins (GreenandKroemer,
2004).The ‘‘indirectmodel’’ proposes that inhealthycellsBAXand
BAK are kept in check by the prosurvival BCL-2 family members
and that BH3-only proteins, when induced by apoptotic stimuli,
bind with higher affinity to the prosurvival BCL-2-like proteins,
thereby unleashing BAX and/or BAK (Youle and Strasser, 2008).
Regardless, experiments with gene-targetedmice and biochem-
ical studies have shown that caspase-8-mediated proteolytic
activation of BID is essential for FAS-induced killing in hepato-
cytes (within the whole animal) (Kaufmann et al., 2007; Yin et al.,
1999) and pancreatic b cells (in culture) (McKenzie et al., 2008).
In contrast, BID is dispensable for Fas-induced apoptosis in
lymphoid cells (both in culture and within the whole animal) and
accordingly, in contrast to FAS- or FASL-deficient mice, Bid/
mice do not develop lymphadenopathy or autoimmunity (Kauf-
mann et al., 2007, 2009). The reasons for this discrepancy in
FAS-induced apoptosis signaling between so-called type 1
(e.g., lymphocytes) and type 2 (e.g., hepatocytes) cells are pres-
ently unclear (Scaffidi et al., 1998), but they may be due to differ-
ences in FAS aggregation or internalization or differences in the
extent of caspase activation or the amount of substrates that
must be proteolyzed for the cells to die (Peter et al., 2007).
Some time ago, it was proposed that FAS-induced apoptosis
occurs not only when FASL-expressing killer cells engage FAS+
target cells, but also when cells are treated with certain chemo-
therapeutic drugs or g-radiation (Debatin and Krammer, 2004). It
was suggested that these cytotoxic stimuli induce FASL expres-
sion (via ceramide induction) and/or increase surface membrane
deposition of Fas via a P53-dependent mechanism, both
processes ultimately leading to autocrine or paracrine FASL-
FAS-induced apoptosis. Studies with cells from Faslpr/lpr mice
did, however, show that g-irradiation and chemotherapeutic
drugs do not require Fas to trigger apoptosis (Newton and
Strasser, 2000). Moreover, experiments with primary cells from
mutant mice lacking FADD (Newton et al., 1998; Newton and
Strasser, 2000; Yeh et al., 1998; Zhang et al., 1998) or cas-
pase-8 function (Salmena et al., 2003; Varfolomeev et al.,
1998) demonstrated that ‘‘death receptor’’ signaling in toto is
not required for these pathways to apoptosis. Although we
cannot rule out the possibility that the mechanisms regulating
apoptosis differ markedly among distinct tumor cells, expression
of dominant-negative FADD, CRMA, or c-FLIP had no impact on
chemotherapeutic drug-induced killing of a collection of
lymphoma-derived cell lines, demonstrating that FADD and cas-
pase-8 are dispensable for this process in at least certain
cancers (Strasser et al., 1995, 2000). We surmise that increased
expression of FAS, FASL, and certain other members of these
receptor and ligand families in chemotherapeutic drug-treated
or g-irradiated cells is a consequence of cellular stress. Although
this process is not required for the death of these cells, it may be
exploited therapeutically as illustrated by the synergistic effects
of TRAIL (APO-2L, a TNF cytokine family member) and certain
chemotherapeutic drugs (e.g., 5-fluoro-uracil) in the killing of
certain tumor cells (Ashkenazi et al., 1999).
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mediated recruitment and activation of caspase-8 are essential
for FAS- and all death receptor-induced apoptosis and that the
BH3-only protein BID is critical for this cell killing in some, albeit
not all, cell types.
The Role of FASL-FAS-Induced Apoptosis in Normal
as well as Pathological Killing of Target Cells
Both classical CD8+ cytotoxic T cells as well as a portion of acti-
vated CD4+ T cells express FASL on their surface in membrane-
bound form (mFASL). Cleavage by a metallo-protease causes
shedding of FASL and the resulting soluble FASL, sFASL, can
still bind FAS (Tanaka et al., 1995, 1998). Studies with various
forms of FASL that were produced in E. coli or transfected
mammalian cell lines have indicated that mFASL kills target cells
via FAS activation much more potently than does sFASL
(Schneider et al., 1998; Suda et al., 1997; Tanaka et al., 1998).
This is consistent with the notion that extensive aggregation of
multiple preassembled FAS trimers and not only FASL trimer-
FAS trimer interaction is required for apoptosis induction (Siegel
et al., 2000). There is also some confusion in the literature based
on the findings that some cultured cell lines shed mFASL-
bearing vesicles into the supernatant. Although such vesicles
can kill FAS+ cells in vitro (Schneider et al., 1998), the physiolog-
ical relevance of this process is currently unclear.
Comparison of T cells lacking both functional FASL and per-
forin (Faslgld/gldPrf1/) with Prf1/ T cells demonstrated that
these two cell death-inducing proteins account for most killing
activity of cytotoxic T cells and NK cells (Ka¨gi et al., 1994),
possibly with some additional contribution by TNF-a. Whereas
FASL normally contributes to the killing of virus-infected,
damaged, or excess cells, abnormally increased FASL-induced
apoptosis of cells that should not be killed has been implicated
as a cause of certain immuno-pathological disorders. For
example, it has been shown that acute graft-versus-host (GvH)
disease in mice can be prevented by combined treatment with
neutralizing antibodies to FASL plus TNF-a (Hattori et al.,
1998). Moreover, FASL was found to be critical for the patholog-
ical killing of hemopoietic progenitors during cytomegalovirus
(CMV) infection (Mori et al., 1997). Interestingly, transfer of
lymphocytes from Faslpr/lprmutant mice into congenic recipients
elicits fatal GvH. This is due to the fact that Fas-deficient T cells
produce abnormally high amounts of mFASL, which kill FAS+
target cells within the host (Watanabe et al., 1995), because
transfer of lymphocytes from FASL-FAS doubly deficient
(Faslgld/gldFaslpr/lpr) mice does not cause GvH disease (Zhu
et al., 2000). When the Faslpr mutation was crossed onto the
NOD background, it was observed that such NOD-Faslpr/lpr
mice do not develop diabetes and therefore concluded that
FASL-FAS signaling is critical for the pathological destruction
of islet b cells in type I diabetes (Chervonsky et al., 1997). The
interpretation of this finding is, however, confounded by the
complication that these animals rapidly develop profound
lymphadenopathy and that Faslpr/lpr (and Faslgld/gld) mice actually
become highly immunocompromised when they develop lymph-
adenopathy. Indeed, experiments in which islets from NOD-
Faslpr/lpr mice were transplanted into NOD mice demonstrated
that FASL-FAS signaling played only a minor role in b cell
destruction in these diabetes-prone animals (Allison andStrasser, 1998). Conversely, experiments in which diabetogenic
T cells from NODmice were injected into NOD-Faslpr/lprscid/scid
recipients (precluding excess FASL expression in the host)
showed that FAS contributes to b cell destruction, at least within
this context (Su et al., 2000). Analysis of perforin-deficient NOD
mice revealed that as for the physiological killing of virus-in-
fected target cells, the perforin-granzyme system plays a major
role in the pathological killing of b cells in type I diabetes (Ka¨gi
et al., 1997). On the basis of all these data, we conclude that per-
forin plays the principal and FASL a contributory role in b cell
destruction during the development of type I diabetes.
Although FASL has been widely reported to be expressed
predominantly (perhaps exclusively) in antigen-stimulated
T lymphocytes (both CD8+ and also some CD4+ T cells) and
NK cells (Krammer, 2000; Mabrouk et al., 2008; Nagata, 1997),
some reports indicated that in certain tissues, such as the testis,
thyroid, or eye, nonhemopoietic cells can express FASL and
thereby kill infiltrating T cells to establish an immune-privileged
niche (Bellgrau et al., 1995). However, subsequent studies with
transplantation of pancreatic islets transgenically engineered
to express FASL ectopically indicated that FASL expressed on
nonhemopoietic cells may not be critical to establish immune
privilege (Allison et al., 1997). It has also been proposed that
FASL expression on cancer cells may render them refractory
to immune attack by engendering them with the ability to kill
FAS+ tumor infiltrating lymphoid and myeloid cells, but this so-
called ‘‘tumor counter-attack’’ hypothesis has also been ques-
tioned (Restifo, 2000). Indeed, enforced expression of FASL on
certain tumor cells was found to enhance rather than delay their
destruction in transplant recipients (Igney et al., 2000). At least
some of the confusion concerning the expression of FASL may
be due to the use of unreliable reagents for its detection. The
generation of gene-targeted knock-in mice (and tumors derived
from them) with inducible deletion of the Fas (Hao et al., 2004) or
Fasl (Mabrouk et al., 2008) genes are expected to resolve some
of these controversies.
The Role of FASL-FAS-Induced Apoptosis
in Lymphocyte Homeostasis
Mice lacking FAS or FASL develop progressive lymphadenop-
athy, which predominantly involves the so-called ‘‘unusual’’
(Thy-1+CD4CD8TCRa/b+B220+) T cells, which are thought to
derive from conventional T cells that have been repeatedly acti-
vated in vivo via their TCR complex (Krammer, 2000; Nagata,
1997). These mutant mice do, however, also accumulate
several-fold increases in conventional CD4+ as well as CD8+
T lymphocytes and B lymphocytes (Krammer, 2000; Nagata,
1997). This led to the conclusion that FASL-FAS signaling plays
a critical role in the homeostasis of the lymphoid system, most
likely by killing unwanted cells at one or several developmental
checkpoints. During both B aswell as T lymphopoiesis in primary
lymphoid organs, apoptosis plays a critical role in the killing of
cells that are either ‘‘useless’’ or ‘‘potentially dangerous’’
(Strasser, 2005). For example, immature lymphoid cells that
failed to productively rearrange the V, (D), and J gene segments
encoding one of their IG or TCR chains and therefore cannot
express surface antigen receptors (BCR or TCR) are deleted as
are those expressing antigen receptors that bind self-
antigens with high affinity (Strasser, 2005). Because TCRImmunity 30, February 20, 2009 ª2009 Elsevier Inc. 183
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cell lines requires FASL-FAS signaling (reviewed in Krammer
[2000]; Nagata [1997]), it was hypothesized that FAS-induced
apoptosis may be critical for the deletion of autoreactive thymo-
cytes and immature B cells in the bone marrow. Although some
studies provided evidence that FAS is essential for the deletion
of thymocytes specific for so-called endogenous or experimen-
tally applied super-antigens (antigens that are presented by
antigen-presenting cells [APC] to T cells as full proteins associ-
ated with MHC molecules and not like conventional antigens as
peptide fragments embedded within the MHC), this is controver-
sial (Villunger et al., 2004). More definitive experiments with TCR
or BCR transgenic mouse models confirmed that FASL and FAS
are dispensable for the deletion of autoreactive thymocytes (Sid-
man et al., 1992) as well as autoreactive B cells developing in the
bone marrow (Rubio et al., 1996), respectively. Further studies
with TCR transgenic mice showed that FAS is also not required
for the rapid death of naive T cells that occurs upon their transfer
into hosts expressing the cognate antigen (Davey et al., 2002). In
fact, studies with transgenic or gene-targeted mice that lack
FADD (Newton et al., 1998) or caspase-8 function (Salmena
et al., 2003) selectively in T lymphoid cells showed that death
receptor-induced apoptosis signaling in toto is not required for
deletion of autoreactive thymocytes. Instead the process for
killing autoreactive T and B cells during their development and
even in theirmature state relieson theBCL-2-regulatedapoptotic
pathway and is initiated by the proapoptotic BH3-only protein
BIM (Bouillet et al., 2002; Davey et al., 2002; Enders et al., 2003).
Programmed cell death also plays a role in the shut-down of
cellular as well as humoral immune responses (Figure 2; Sprent
and Tough, 2001). In the case of acute immune responses,
such as infection with a nonpersisting pathogen (or injection
with a degradable antigen), foreign antigen-specific T and B cells
can expand several hundred-fold in numbers (Sprent and Tough,
2001). Most differentiate into effector cells (cytotoxic as well as
helper T cells and antibody-producing plasma cells), which
help overcome the pathogens by killing them, either directly or
indirectly through cytokine-mediated activation of cells of the
innate immune system. A small number of activated B and
T cells differentiate into so-called ‘‘memory’’ cells, which are
long-lived and able to respond rapidly in response to challenge
with the same pathogen, thereby providing the organism with
long-lasting immunity (Sprent and Tough, 2001). After pathogens
have been defeated, effector cells are no longer needed and in
fact are potentially dangerous, so most undergo programmed
cell death (Sprent and Tough, 2001). This apoptosis restores
normal cellularity in peripheral lymphoid organs, thereby making
space for the development of immune responses to subsequent
infectious challenges. In addition, apoptosis of activated
lymphocytes minimizes the collateral damage to healthy tissues
that can be caused by the immune effector molecules (e.g.,
inflammatory cytokines, immune complexes, perforin-gran-
zymes) (Sprent and Tough, 2001). In the case of chronic infec-
tions with persistent antigenic challenge, the killing of activated
lymphocytes is critical to achieve a state of cohabitation
between the pathogen and the host, so that the numbers of path-
ogens are kept at an acceptable titer and at the same limiting
immune activation to minimize inadvertent destruction of vital
tissues (Sprent and Tough, 2001).184 Immunity 30, February 20, 2009 ª2009 Elsevier Inc.When FASL and FAS were discovered to be critical for TCR
stimulation-induced AICD of normal cycling T lymphoblasts
and transformed T lymphoma-derived cell lines (reviewed in
Krammer [2000] Nagata [1997]), it was widely speculated that
FASL-FAS-induced apoptosis would also prove to be essential
for the death of antigen-activated T and B cells during shut-
down of immune responses. For the removal of activated
T cells during an acute immune response, however, this model
makes little sense. The induction of FASL on T lymphoid cells
undergoing AICD requires TCR stimulation, but during termina-
tion of acute immune responses, T cells die after pathogens
have been expelled, a timewhen no antigen is present to activate
the TCR. Indeed, although it was initially reported that FASL and
FAS are critical for the killing of activated T cells during termina-
tion of acute immune responses (e.g., in TCR transgenic mice
injected with the cognate peptide), later experiments with mice
injected with a single dose of the super-antigen staphylococcus
enterotoxin B (SEB) (Hildeman et al., 2002) or challenged with
herpes simplex virus (HSV, causing nonpersistent infection) (Pel-
legrini et al., 2003) demonstrated that FAS and TNF-R1 death
receptor signaling are dispensable for this process. In fact, the
killing of antigen-activated T cells during termination of acute
immune responses appears to be initiated by a decline in the
levels of cytokines that promote their survival (e.g., IL-2, IL-7),
which triggers the BCL-2-regulated apoptotic pathway predom-
inantly through activation of the BH3-only protein BIM (Figure 2;
Hildeman et al., 2002; O’Connor et al., 1998; Pellegrini et al.,
2003).
In contrast to acute immune responses, pathogens and their
antigens persist during chronic immune responses, thereby
potentially facilitating repeated stimulation of already activated
T lymphocytes through their TCR, which would then lead to
FASL upregulation and their FAS-induced suicide or fratricide
(Krammer, 2000; Nagata, 1997). Indeed, the first clear demon-
stration for a role of FAS-induced apoptosis in the shut-down
of a T cell immune response came from studies in which mice
were repeatedly injected with SEB (Strasser et al., 1995), thereby
mimicking a chronic infection. More recently, experiments with
mice infected with persistent viruses (e.g., LCMV or mouse
gamma herpes virus) showed that the killing of activated
T cells during the ensuing chronic immune response requires
both FASL-FAS and the proapoptotic BH3-only BCL-2 family
member BIM (Figure 2; Hughes et al., 2008; Hutcheson et al.,
2008;Weant et al., 2008). Thus, their death appears to be caused
by FASL-FAS signaling, triggered by repeated TCR stimulation,
and by the BCL-2-regulated apoptotic pathway, which presum-
ably is initiated by growth factor deprivation-induced induction
of BIM.
B lymphoid cells express Fas on their surface and can be killed
by treatment with FASL or agonistic FAS-specific antibodies
(Krammer, 2000; Nagata, 1997) and, accordingly, FASL-FAS
signaling was found to play a critical role in the control of humoral
immune responses (Figure 2). The consequences of FAS activa-
tion in B cells are critically influenced by the activity of other
signaling pathways. BCR crosslinking or CD40 stimulation,
particularly their combination, protect B lymphocytes from
FAS-induced apoptosis (Rothstein et al., 1995). This protection
appears to be mediated by activation of REL-NF-kB transcrip-
tion factors, which activate expression of c-FLIP (Hennino
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Figure 2. Fas-Mediated Death Receptor Signaling and Bcl-2-Regulated Apoptosis Signaling in the Killing of Activated T and B Lymphocytes
This figure shows the mechanisms that control FASL-FAS-induced apoptosis and BIM-dependent BCL-2-regulated apoptosis in activated T and B cells during
shutdown of acute or chronic immune responses. During shutdown of an acute T cell immune response (left side, top), the reduction in the concentrations of
cytokines, such as IL-2 and IL-7, leads to a reduction in PI3K and AKT. This causes activation of the transcription factor FOXO3A, which promotes transcriptional
induction of the proapoptotic BH3-only protein BIM and consequently activation of the BCL-2-regulated apoptotic pathway. Furthermore, reduced antigen
concentration leads to diminished TCR stimulation and consequently reduced activation of the REL-NF-kB and NF-AT transcription factors, which are known
to promote expression of prosurvival proteins, such as BCL-2 or BCL-XL.
As in shutdown of acute T cell immune responses, during shutdown of a chronic T cell response (left side, bottom), the availability of growth factors is also
reduced, leading to the activation of BIM and initiation of the BCL-2-regulated apoptotic pathway as described above. In addition, repeated TCR ligation triggers
FASL expression on T cells leading to autocrine and/or paracrine stimulation of FAS, caspase-8 activation, activation of effector caspases, and consequently
apoptosis as shown in Figure 1.
During shutdown of a B cell immune response (left side), FAS is induced on B cells and can be activated by FASL presented on T helper cells. This leads to B cell
apoptosis when CD40 signaling is diminished because of reduced expression of CD40L on T helper cells, because this causes a reduction in the activity of the
REL/NF-kB and NF-AT transcription factors, which normally promote expression of prosurvival proteins, such as c-FLIP. In addition, a reduction in the concen-
tration of growth factors can lead to BIM upregulation as described above.
Abbreviations: gc Receptors, common gamma chain containing cytokine receptors (e.g., receptors for IL-2, IL-4, IL-7, IL-15); DISC, death-inducing signaling
complex; GF-Rec., growth factor receptors; TCR, T cell antigen receptor; PI3K, phosphoinositide 3-kinases; BCR, B cell antigen receptor; C8, caspase 8.et al., 2001). In fact, in combination with BCR-crosslinking and
CD40 activation, FAS ligation may actually contribute to activa-
tion, proliferation, and differentiation of B cells, rather than
trigger their apoptosis (Figure 2, and see below).
Germinal centers are anatomical niches within secondary
lymphoid organs composed of B cells, specific CD4+ T helper
subsets, and follicular dendritic cells. In these locations, B cells
and intrafollicular CD4+ T cells recognizing the same antigenic
compound are activated by interaction with each other and
antigen retained on the follicular dendritic cells. This results in
stimulation of B cells leading to their proliferation, hypermuta-tion of the rearranged and expressed Ig variable region genes,
and differentiation into antibody-secreting plasma cells on one
hand and long-lived memory B cells on the other. During and
after the germinal center reaction, activated B lymphocytes
are subject to stringent selection. Only those B cells expressing
high-affinity antibodies for the antigen (due to Ig V gene somatic
hypermutation) can compete successfully for the limiting
amount of antigen and T cell help (CD40L) and thereby gain
survival signals through their BCR and CD40—low-affinity anti-
body-expressing B cells die by neglect. Theoretically, IGV gene
hypermutation can give rise to B cells expressing BCRs specificImmunity 30, February 20, 2009 ª2009 Elsevier Inc. 185
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showed that such autoreactive B cells are deleted by apoptosis
(Shokat and Goodnow, 1995). FASL and FAS play critical roles
in the control of B lymphocyte survival during the germinal
center reaction (Figure 2; Krammer, 2000; Nagata, 1997). Acti-
vated B lymphocytes bearing low-affinity BCR are killed when
FAS on their surface is ligated by FASL expressed on intrafollic-
ular CD4+ T cells and they fail to receive a prosurvival signal
through their BCR and CD40 (Figure 2). In experimental models
for deletion of autoreactive B lymphocytes within germinal
centers, it was found that both FAS death receptor signaling
as well as the BCL-2-regulated apoptotic pathway contribute
to B cell killing (Figure 2; Rathmell et al., 1995). This is reminis-
cent of the finding that both of these pathways (the latter initi-
ated by the proapoptotic BH3-only protein BIM) contribute to
the killing of T cells that are chronically activated by path-
ogen-derived antigens or self-antigens (Hughes et al., 2008;
Hutcheson et al., 2008; Weant et al., 2008). In further support
of a collaboration of the FAS death receptor and the BCL-2-
regulated apoptotic pathways in the deletion of autoreactive
B and T cells in peripheral lymphoid organs and establishment
of immunological tolerance, it was found that BCL-2 overex-
pression (Strasser et al., 1995) or loss of BIM (Hughes et al.,
2008; Hutcheson et al., 2008; Weant et al., 2008) greatly accel-
erate and enhance lymphadenopathy and autoimmunity in
FAS- or FASL-deficient mice. BIM was shown to play a critical
role in the killing of activated B cells and IG-secreting plasma
cells during shut-down of acute humoral immune responses
(Fischer et al., 2007), and this BH3-only protein is probably acti-
vated by the decline in the concentration of growth factors
(Figure 2).
Collectively, these results demonstrate that FAS and death
receptor signaling in toto play no role in the deletion of autoreac-
tive B or T cells during their development in primary lymphoid
organs. Instead these pathways are critical, either alone or in
combination with the BCL-2-regulated apoptotic pathway, for
the killing of antigen-activated lymphocytes during termination
of immune responses.
Unexpected Lessons from Deletion of Fas
in Select Cell Types
Because FAS is expressed on a broad range of lymphoid,
myeloid, and also nonhemopoietic cell types, it is not immedi-
ately clear in which cells FAS function must be lost to cause
the lymphadenopathy and autoimmunity observed in FAS-defi-
cient mice and humans (Krammer, 2000; Nagata, 1997). This
important question has been addressed by generating FAS-defi-
cient mice (Faslpr/lpr) that express a FAS transgene in either B
and/or T cells (Fukuyama et al., 1998, 2002; Komano et al.,
1999) or mice in which the sequences within the Fas gene that
encode the death domain have been flanked by loxP sites and
can therefore be deleted in a cell type-specific or inducible
manner (via transgenic mice expressing the CRE recombinase
under control of a cell type-specific or inducible promoter)
(Hao et al., 2004, 2008). When interpreting data from the latter
mice (and the Fas/ mice [Adachi et al., 1995]), it is important
to remember that cells that have undergoneCRE-mediated dele-
tion of these sequences can still express FAS (devoid of the
death domain) on their surface. It has been speculated that186 Immunity 30, February 20, 2009 ª2009 Elsevier Inc.such a truncated FAS may still be able to exert some nonapop-
totic functions either directly or indirectly by so-called ‘‘reverse
signaling’’ via FASL (Peter et al., 2007; see also below). It must
also be borne in mind that several of these experiments were
performed on different inbred or even mixed genetic back-
grounds, so the results may not always be directly comparable,
because the impact of the Faslpr and the Faslgld mutations are
greatly affected by genetic background. Nonetheless, these
studies revealed many interesting aspects of the role of FASL-
FAS signaling in the control of the normal immune system and
prevention of autoimmunity (see references above). Transgenic
expression of normal amounts of FAS in T cells of Faslpr/lpr
mice prevented lymphadenopathy, in particular the accumula-
tion of the unusual TCR-a/b+CD3+CD4CD8B220+ T cells,
but these animals still produced autoantibodies and developed
SLE-like glomerulonephritis (Fukuyama et al., 1998). In contrast,
transgenic expression of FAS on B cells protected Faslpr/lpr
mutant mice from SLE-like autoimmunity although abnormal
accumulation of T cells, including TCR-a/b+CD3+CD4CD8
B220+ ones, was not affected (Komano et al., 1999). Remark-
ably, with increasing age these mice developed a severe deficit
in B cells and antibody-secreting plasma cells and this appeared
to be due to the excess FASL produced by the abnormally accu-
mulating T cells (Watanabe et al., 1995) triggering apoptosis of B
lymphoid cells via the transgene-encoded FAS (Komano et al.,
1999). Generation of Faslpr/lpr mutant mice that lack B cells
because they carry a homozygous deletion of the JH gene locus
(precluding IGH expression) showed that B cells are required for
the SLE-like autoimmunity but dispensable for the T cell-associ-
ated lymphadenopathy that is caused by defects in FAS (Shlom-
chik et al., 1994).
Selective loss of FAS on T cells (in Cd4-Cre or lck-Cre trans-
genic FasloxP/loxP mice) caused progressive lymphopoenia on
the C57BL/6 background albeit to a lesser extent on a (C57BL/
6xMRL) F1 background (Hao et al., 2004). This cell loss was
mediated by the excessive FASL produced by the FAS-deficient
T lymphocytes (Watanabe et al., 1995), because it could be pre-
vented by injection with neutralizing antibodies to FasL (Hao
et al., 2004). B lymphocyte deletion in these animals was prob-
ably mediated directly, as they express FAS on their surface,
but such a process cannot explain the loss of T cells, since
they lack FAS. Their progressive disappearance may be due to
an indirect mechanism, which involves FASL-mediated killing
of FAS+ cells that deliver critical survival signals to T lympho-
cytes. B lymphocytes account for some, albeit clearly not all,
of these survival signals, because T cell lymphadenopathy with
CD4+, CD8+, as well as the unusual TCR-a/b+CD3+CD4
CD8B220+ T cells is substantially diminished (although not
abrogated) in B cell-deficient Faslpr/lpr mutant mice compared
to control Faslpr/lpr animals (Shlomchik et al., 1994).
Loss of FAS on B cells or on both B cells plus T cells (in Cd19-
Cre transgenic or Cd19-Cre-Cd4-Cre bitransgenic FasloxP/loxP
mice) elicited lymphadenopathy, hypergammaglobulinemia,
and autoantibody production (Hao et al., 2004, 2008). All of these
abnormalities developed in these animals, however, to a consid-
erably lower extent and more slowly compared to animals with
loss of FAS in all tissues or in all hemopoietic cells (Mx-Cre trans-
genic FasloxP/loxP mice injected with poly-IC). Interestingly,
specific loss of FAS-mediated apoptosis in dendritic cells (with
Immunity
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features of autoimmunity, such as lymphoid hyperplasia and
production of antinuclear autoantibodies (Stranges et al.,
2007). Collectively, these results demonstrate that FAS imposes
a barrier against lymphadenopathy and autoimmunity by acting
not only in B and T cells but by functioning also in certain other
hemopoietic and possibly nonhemopoietic cell types.
A recent study (with IgHg1-Cre transgenic FasloxP/loxP mice, in
which the Fas gene is deleted only in B cells that have switched
from IGM to IGG production) has shown that FAS plays a partic-
ularly prominent role in the control of B as well as T cell homeo-
stasis and autoantibody production in germinal center B cells
(Hao et al., 2008). All immune defects caused by loss of FAS in
these IGG+ B cells could be prevented by loss of T cells (by dele-
tion of the locus encoding the b chain of the TCR) or by blockade
of the mutual costimulatory signals that are exchanged between
activated B cells and activated CD4+ T cells within germinal
centers (by deletion of the Cd28 gene) (Hao et al., 2008). These
findings are consistent with the model (see also above)
that antigen-stimulated B cells in germinal centers, which as
a result of IGV gene somatic hypermutation express either
a self-antigen-specific BCR or a BCR with low affinity for the
immunogen, are killed by encountering FASL on activated intra-
follicular CD4+ T cells. It will be interesting to test this hypothesis
by generating mutant mice that lack FASL exclusively within this
T cell subset, and to examine how T cells recognize autoreactive
B cells to kill them via FASL-FAS signaling.
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Figure 3. Nonapoptotic Signaling by
Components of the Death Receptor
Pathway
This figure shows the two distinct modes of cas-
pase-8 activation: the well-known death receptor
apoptotic pathway involving caspase-8 autopro-
cessing (shown on the left) followed by either
direct activation of effector caspases or proteolytc
activation of the BH3-only protein BID to activate
the BCL-2-regulated apoptotic pathway (see also
Figure 1). The caspase-8-related protein c-FLIP
mainly acts as a catalytically inactive caspase-8
substitute competing for the binding to FADD,
thereby limiting recruitment and activation of cas-
pase-8 and thus blocking apoptosis initiation.
However, c-FLIP has also been shown to promote
caspase-8 recruitment and activation in certain
circumstances. The right side illustrates the pres-
ently only poorly understood pathway by which
FADD and caspase-8 promote cellular activation,
proliferation, and differentiation without the need
of self-processing. For this pathway, neither the
upstream activators (death receptors?) nor the
substrates of caspase-8 are identified. Abbrevia-
tions: DISC, death-inducing signaling complex;
MOMP, mitochondrial outer membrane permeabi-
lization; Cyt. C, cytochrome C; c-FLIP, cellular
form of FADD-like IL-1b-converting enzyme-inhib-
itory protein; casp-8, caspase-8.
Nonapoptotic Activities of
Components of the Death Receptor
Signaling Machinery
It is firmly established that several
members of the TNF-R family, including
some that are classified as death recep-
tors (e.g., TNF-R1), and their corresponding ligands exert (either
exclusively or in addition to their prodeath activity) nonapoptotic
functions, such as the induction of cellular activation, prolifera-
tion, differentiation, or migration (Figure 3; Krammer, 2000; Na-
gata, 1997; Peter et al., 2007). Also for FAS activation, several
investigations (even quite early ones in the course of studies of
this receptor) have observed nonapoptotic consequences in
a range of cell types. For example, FAS was reported to promote
proliferation of human T lymphocytes as well as growth factor-
deprived fibroblasts and maturation of dendritic cells in culture
(reviewed in Peter et al. [2007]). Perhaps most impressively
(and intriguingly), although injection of agonistic FAS-specific
antibodies (Ogasawara et al., 1993) or FASL causes fatal hepa-
titis in mice (Huang et al., 1999), FAS stimulation (with agonistic
FAS-specific antibodies) was reported to accelerate liver regen-
eration in mice subjected to partial hepatectomy (reviewed in
Peter et al. [2007]). Interestingly, a delay in liver regeneration
was seen in Faslpr/lpr mutant mice as well as TNF-R1-deficient
animals (reviewed in Peter et al. [2007]), implicating both of these
death receptors in this process. The mechanisms by which FAS
ligation stimulates cell proliferation and/or maturation are pres-
ently unclear, but the REL/NF-kB and MAP kinase signaling
pathways have both been implicated (reviewed in Peter et al.
[2007]). Interestingly, normal liver regeneration after partial
hepatectomy was seen in Faslpr(cg)/lpr(cg) mutant mice although
Faslpr/lprmice exhibited a significant delay. The Faslpr(cg)mutation
causes an amino acid substitution within the death domain ofImmunity 30, February 20, 2009 ª2009 Elsevier Inc. 187
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recruitment of FADD into the DISC. This may indicate that FAS-
induced cell growth, at least in hepatocytes, occurs by a mecha-
nism that is independent of FADD and therefore probably also
caspase-8. This idea is, however, contradicted by the finding
that selective loss of caspase-8 in hepatocytes (in Alb-Cre trans-
genic Casp8loxP/loxP mice) impairs liver regeneration after partial
resection (Ben Moshe et al., 2007).
Although the physiological importance of nonapoptotic
signaling pathways activated by Fas remains controversial
(Krammer, 2000; Nagata, 1997; Peter et al., 2007), it is now
widely accepted that essential components of the death
receptor machinery also perform critical nonapoptotic roles
(Figure 3; Newton and Strasser, 2003). This was first discovered
when it was observed that blocking the function of FADD does
not only inhibit FASL-induced apoptosis of T lymphocytes but
also impairs their activation and proliferation in response tomito-
genic or antigenic stimulation (Newton et al., 1998; Zhang et al.,
1998). Subsequently, it was found that FADD is also critical for
pre-TCR-induced proliferation of T cell progenitors (pro-T3
and/or pro-T4 cells) in the thymus (Newton et al., 2000), TLR
(Toll-like receptor)-mediated innate immune responses (Bala-
chandran et al., 2004) (a process that notably also requires
FADD in Drosophila [Hoffmann, 2003]), TLR-induced prolifera-
tion of B cells, and cytokine-induced proliferation of myeloid
progenitors (Pellegrini et al., 2005). Experiments with gene-tar-
geted mice in which the Casp8 gene was deleted in a cell
type-specific manner (with crosses with appropriate Cre trans-
genic mice) confirmed that most of these processes require
not only FADD but also caspase-8 (Kang et al., 2004; Salmena
et al., 2003). In addition, caspase-8 was found to be essential
for cytokine-induced monocyte differentiation in culture (Kang
et al., 2004) and, as already discussed above, for liver regenera-
tion within the whole animal after partial hepatectomy (Ben
Moshe et al., 2007). Remarkably, loss of caspase-8 (Varfolomeev
et al., 1998), its activator FADD (Yeh et al., 1998), or its modulator
c-FLIP (Yeh et al., 2000) in all tissues causes early embryonic
lethality (E10.5) because of nonapoptotic defects in vascular
development and early hemopoiesis. It is presently not fully
resolved whether these nonapoptotic processes require the
enzymatic activity of caspase-8 or some other function of this
protease, but there is evidence that the former may well be the
case, at least for some. For example, in tissue culture, enzymatic
inhibitors of caspase-8 were found to impair mitogen- or
antigen-induced T cell proliferation (Kennedy et al., 1999) and
cytokine-induced proliferation of myeloid progenitors (Pellegrini
et al., 2005). We anticipate that the generation of gene-targeted
mice that contain amutation that disables the catalytic activity of
caspase-8 may resolve this issue.
Accepting that FADD-mediated activation of caspase-8 is
essential for the aforementioned nonapoptotic processes, one
must ask the following two questions: (1) how are FADD and
caspase-8 activated during these processes and (2) what intra-
cellular nonapoptotic signaling pathways are triggered by cas-
pase-8 (Figure 3)? Both of these important questions are
currently unresolved and are considered by some as a ‘‘holy
grail.’’ Death receptors are the only presently known activators
of FADD and caspase-8, and it is interesting to contemplate
that low level (‘‘tonic’’) autocrine or paracrine death ligand-death188 Immunity 30, February 20, 2009 ª2009 Elsevier Inc.receptor signaling may play a critical role in cell fate determina-
tion during embryogenesis and in other scenarios (see above).
Such tonic autocrine and/or paracrine TNF-TNF-R1 signaling
has recently been found to play an essential role in the response
of tumor cells to SMAC (second mitochondria-derived activator
of caspases, also called DIABLO, direct inhibitor of apoptosis
protein binding-protein with low pI) mimetic IAP (inhibitor of
apoptosis protein) inhibitory drugs. There is, however, currently
no evidence that death receptors and their ligands are essential
for the established nonapoptotic functions of FADD and cas-
pase-8. None of the gene-targeted mice lacking one or even
two death receptors (FAS, TNF-R1, DR3, or TRAIL-R) or death
ligands exhibit early embryonic lethality or defects in mitogen-
induced activation and proliferation of B and/or T lymphocytes
(reviewed in Newton and Strasser [2003]; Peter et al. [2007]). It
remains, however, possible that there is greater functional over-
lap between death receptors than currently anticipated, and
defects in vascular development during embryogenesis or
mitogen-induced T cell proliferation, akin to those caused by
loss of FADD or caspase-8, may become apparent only in
mice lacking a combination of three or all four of these receptors
or their ligands. Alternatively, there may be mechanisms for
FADD and caspase-8 activation that are independent of death
receptors (Figure 3). Perhaps biochemical studies, with pull-
down of FADD and/or caspase-8 containing complexes from
cells in which these proteins fulfil a nonapoptotic function, will
be able to identify the mechanisms of their activation.
There is increasing evidence that FADD and caspase-8 must
undergo different post-translational modifications and must be
localized to different subcellular compartments depending on
whether they mediate cell death (e.g., after treatment of T cells
with FASL) or transduce cellular activation signals (e.g., after
mitogenic stimulation of T cells) (O’Reilly et al., 2004). For
example, a single amino acid within FADD was reported to be
critical for its action in cell proliferation but apparently has no
role in FADD-mediated apoptosis (Hua et al., 2003). Interestingly,
T cells undergoing FASL-induced apoptosis contain a large
amount of caspase-8 activity and most of it is found in the
cytosol, whereas mitogenically activated T cells have consider-
ably lower levels of caspase-8 activity, which is mostly concen-
trated in discrete foci at the plasma membrane (Koenig et al.,
2008). Studies with mice expressing mutant forms of caspase-8
have shown that although autoproteolysis is required for the
ability of this caspase to mediate FASL-induced cell killing, this
processing is dispensable for its nonapoptotic functions
(Figure 3; Kang et al., 2008). This is consistent with the notion
that caspase-8 must be released from the DISC to gain access
to critical substrates (i.e., the zymogens of the ‘‘effector’’ cas-
pases) within the cytosol to effect cell killing, but must be
retained at the plasma membrane to mediate its nonapoptotic
functions. Identification of the substrates that are cleaved by
caspase-8 near the plasma membrane is expected to greatly
advance our understanding of its function in nonapoptotic
processes. Although one study reported that caspase-8 is
essential for TCR-ligation-induced REL/NF-kB activation, others
found that REL/NF-kB, MAP kinase, and NFAT activation all
occur normally in the absence of FADD or caspase-8 function
in TCR- or TLR-stimulated T and B cells, respectively (Beisner
et al., 2003; Newton et al., 2001; Salmena et al., 2003). It is
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FADD and caspase-8 play an essential nonapoptotic function,
such as vascular development during embryogenesis, there is
no evidence that REL/NF-kB plays a critical role. We find it
remarkable how diverse the processes actually are in which
FADD and caspase-8 play a critical nonapoptotic function, im-
pacting on the responses of cells to ligation of cytokine recep-
tors, antigen receptors, or TLRs. Interestingly, many of the non-
apoptotic processes in which FADD and caspase-8 play a role
involve transition of cells from the quiescent (G0) into the cycling
state. Therefore, and because pathways that are critical for
cellular activation and proliferation (e.g., activation of REL/NF-
kB, MAPK, NFAT) occur normally in their absence, we speculate
that FADD and caspase-8 trigger a nonapoptotic function that
modifies or facilitates the responses of other signaling pathways
within cells. Alternatively (and not mutually exclusive), it is
possible that FADD and caspase-8 play a critical role in the regu-
lation of autophagy (Bell et al., 2008), a mechanism for procure-
ment of energy andmetabolites (e.g., in starved or stressed cells)
that impacts on many cellular and developmental processes. As
mentioned above, identification of binding partners for FADDand
substrates of caspase-8 within mitogenically activated T cells or
cytokine-stimulated monocytes may open an entire new area of
investigation.
Collectively, these observations demonstrate that FADD and
caspase-8 are not only essential for death receptor-induced
apoptosis signaling but also have critical, albeit biochemically
still ill-defined, roles in cellular activation, proliferation, and differ-
entiation.
Conclusions and Perspectives
Wenowhave a very good framework of understanding of the role
of FASL-FAS-induced apoptosis in the control of the immune
system and its critical function as a guardian against autoim-
mune disease and certain lymphoid malignancies. This knowl-
edge is being exploited to develop novel cancer therapies,
such as TRAIL-R-specific agonists or SMAC/DIABLO mimetics.
Many anticancer drugs have proven to be efficacious in the treat-
ment of (certain) autoimmune diseases (e.g., Rituximab, CD20-
specific antibodies), so it is possible that the aforementioned
compounds that are currently being developed may also
become useful in the treatment of such diseases.
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